For the reason that people that have the APOE e4 gene variant show up to have a larger hazard of significant complications, the FDA suggests staying tested for the gene variant before starting treatment with lecanemab or donanemab.The test is applied to evaluate early signs of dementia (the progressive lack of intellectual performing, Specifically